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Mental Disability Law and CRISPR: Can Current Legal Standards Protect Vulnerable 
Populations from Overzealous Researchers? 
Catriona Coffey* 
I. Introduction 
In 2012, the imaginings of science fiction came true when scientists revealed that newly-
developed technology could enable highly-specified genetic manipulation.1  This technology, 
largely known as CRISPR,2 revolutionized the field of genetics by making gene editing “faster, 
cheaper, more accurate, and more efficient than other existing genome editing methods.”3  As a 
result, the medical field is increasingly turning to gene editing as a potential treatment option for 
innumerable conditions with a genetic basis.  Scientists are rapidly pursuing clinical applications, 
and it is time for leaders, legislators, and regulators to carefully examine the potential impacts of 
this technology on vulnerable members of society. The law as it currently stands provides 
insufficient protection from the potential harm posed by unwelcome applications of gene editing 
technology. This Comment will provide an overview of current laws related to CRISPR 
technology and suggest possible solutions for the regulation of its more immediate applications. 
A. Technology Overview  
 The field of molecular genetics is a relatively new area of study, as researchers only began 
to explore genome mechanics within the past century.4  Beginning in the late 1970’s, scientists 
sought to understand how genes in living cells could be manipulated, leading to the development 
 
* J.D. Candidate, 2021, Seton Hall University School of Law; B.A., Boston College. 
1 Mussaad M. Al-Razouki, From Science Fiction to Science Fact: Genetic Engineering, MEDIUM (May 1, 2018), 
https://medium.com/@Mussaad/from-science-fiction-to-science-fact-3a38b110f5d0. 
2 CRISPR is an acronym for “clustered regularly interspaced short palindromic repeats”. What are Genome Editing 
and CRISPR-Cas9?, NATIONAL INSTITUTES OF HEALTH: GENETICS HOME REFERENCE (Aug. 2017), 
https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting. 
3 Id. 
4 Thomas Wirth, Nigel Parker & Seppo Ylä-Herttuala, History of Gene Therapy, 525 GENE 162, 162-63 (2013). 
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of several techniques to add or remove genetic sequences from strands of DNA.5  While the field 
saw massive advances throughout the latter half of the 20th century (due in part to the Human 
Genome Project),6 progress stalled in 1999 after  clinical trial patient Jesse Gelsinger died from an 
intense inflammatory reaction to a single gene therapy injection.7  This tragedy revealed a number 
of problems with the oversight mechanisms and reporting requirements that regulate the field of 
genetic human subject research.8  Since Jesse’s death, geneticists and regulators alike have sought 
to improve the field as a whole, yet biomedical technology continues to far outpace policy and 
regulation.9  The discovery of CRISPR once again presents the challenge of tempering scientific 
promise with an abundance of rightful caution. 
 CRISPR, an acronym for “clustered regularly interspaced short palindromic repeats” 
(indicating the DNA sequences that make CRISPR possible), provides scientists with a method to 
“add[], remove[], or alter[ genetic material] at particular locations in the genome”.10  The 
technology allows for much more targeted gene editing than previous methods because: 
 
5 How Does Genome Editing Work?, NATIONAL INSTITUTES OF HEALTH: NATIONAL HUMAN GENOME RESEARCH 
INSTITUTE (Aug. 3, 2017), https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/How-genome-
editing-works. 
6 The Human Genome Project, NATIONAL INSTITUTES OF HEALTH: NATIONAL HUMAN GENOME RESEARCH INSTITUTE 
(Oct. 7, 2019), https://www.genome.gov/human-genome-project. 
7 Meir Rinde, The Death of Jesse Gelsinger, 20 Years Later, SCIENCE HISTORY INSTITUTE: DISTILLATIONS (June 4, 
2019), https://www.sciencehistory.org/distillations/the-death-of-jesse-gelsinger-20-years-later. 
8 Id. 
9 Id. It is worth noting that CRISPR technology has also created turmoil in the field of patent law, as major institutions 
on each U.S. coast have fought to control intellectual property rights to the technology. While the patent standing of 
CRISPR is outside the scope of this article, control of intellectual property rights to the technology may have 
substantial implications for how CRISPR-related ethical issues evolve. For further discussion, see Megan Molteni, 
Crispr’s Epic Patent Fight Changed the Course of Biology, WIRED (Sep. 11, 2018, 3:42 PM), 
https://www.wired.com/story/crisprs-epic-patent-fight-changed-the-course-of-biology/; Sharon Begley, Patent Office 
Reopens Major CRISPR Battle Between Broad Institute and University of California, STAT (June 25, 2019), 
https://www.statnews.com/2019/06/25/crispr-patents-interference/; Hannah Mosby, Biotechnology’s Great Divide: 
Strengthening the Relationship Between Patent Law and Bioethics in the Age of CRISPR-Cas9, 19 MINN. J.L. SCI. & 
TECH. 565 (2018). 
10 What are Genome Editing and CRISPR-Cas9?, supra note 2. For a more basic overview of CRISPR technology, 




[w]ith CRISPR, researchers create a short RNA template that matches a target DNA 
sequence in the genome. . . Strands of RNA and DNA can bind to each other when 
they have matching sequences. The RNA portion of the CRISPR, called a guide 
RNA, directs Cas9 [CRISPR-associated protein 9] enzyme to the targeted DNA 
sequence. Cas9 cuts the genome at this location to make the edit. CRISPR can make 
deletions in the genome and/or be engineered to insert new DNA sequences.11 
 
This represents a vast improvement in the reliability of gene editing.  Where prior methods were 
resource intensive and technically complex, requiring synthesis of new proteins for each desired 
change, CRISPR represents a much more simplified (and cheaper) means of achieving a more 
precise result.12  Whereas older technologies saw, at best, a ten percent success rate,13  CRISPR 
may provide up to six times the efficiency of these methods “at a small fraction of time and 
price.”14 
 As a result of the tremendous promise that CRISPR holds, “CRISPR-Cas genome editing 
tools have been adopted rapidly in the research community[ and] . . . are quickly finding 
applications in the commercial sector.”15  These potential applications of CRISPR are innumerable 
and may impact human life positively or negatively, both inside and outside the medical field.16  
While the desire to cure insidious genetic diseases is certainly a noble goal, CRISPR technology 
also raises a wide variety of ethical issues that scientists must take into account.17  These concerns 
go beyond germ-line editing (editing of genes that can be passed on to future generations) and 
 




15 Dana Carroll, Genome Editing: Past, Present, and Future, 90 YALE J. OF BIOL. AND MEDICINE 653 (2017). See also, 
What are Genome Editing and CRISPR-Cas9?, supra note 2. 
16 Compare Victor Tangermann, A CRISPR Future: Five Ways Gene Editing Will Transform Our World, FUTURISM 
(Jan. 30, 2018), https://futurism.com/crispr-genetic-engineering-change-world with Heidi Ledford, CRISPR 
Concerns, 538 NATURE 17 (Oct. 6, 2016), 
https://www.nature.com/news/polopoly_fs/1.20713!/menu/main/topColumns/topLeftColumn/pdf/nature.2016.20713
.pdf?origin=ppub. 
17 Arthur L. Caplan, Brendan Parent, Michael Shen & Carolyn Plunkett, No Time to Waste – The Ethical Challenges 




include applications of gene editing to somatic cells (where edits would not be passed to future 
generations).18 
B. The Somatic/Germ-Line Ethical Divide 
An additional aspect of the underlying science—whether manipulated genes could be 
passed on to future generations—complicates the implications of CRISPR technology.  This 
complication arises from the fact that living organisms are composed of two primary cell types.  
Somatic cells, which make up the vast majority of cells in the human body, do not pass their genes 
on to future generations.19  “A somatic cell is any cell of the body except sperm and egg cells.  
Somatic cells are diploid, meaning that they contain two sets of chromosomes, one inherited from 
each parent.  Mutations in somatic cells can affect the individual, but they are not passed on to the 
offspring.”20  Germ-line cells, on the other hand, develop gametes (or sperm and eggs) and do pass 
genetic information, including CRISPR modifications, to future generations.21  This ability (or 
inability) to pass genetic information to future progeny has become the foundation of the present 
CRISPR bioethics debate. 
With the somatic/germ-line distinction forming the dividing line in CRISPR bioethics, 
many bioethics leaders assert that research on somatic application should forge ahead, while a 
voluntary moratorium should be placed on germline editing.22  Although nice in theory, the 
 
18 Id. 
19 Somatic Versus Germinal Mutation, An Introduction to Genetic Analysis, 7th ed. (2000), 
https://www.ncbi.nlm.nih.gov/books/NBK21894/. 
20 “Somatic Cells”, National Human Genome Research Institute, https://www.genome.gov/genetics-
glossary/Somatic-Cells. 
21 Somatic Versus Germinal Mutation, supra note 19. See also “Germ Line”, National Human Genome Research 
Institute, https://www.genome.gov/genetics-glossary/germ-line. 
22 Giulia Cavaliere, Background Paper: The Ethics of Human Genome Editing, WORLD HEALTH ORGANIZATION: 
Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome 
Editing (2019), at 2, (citing Edward Lanphier, Fyodor Urnov, Sarah Ehlen Haeker, Michael Werner & Joanna 




obvious weaknesses in this approach are readily apparent.  Due in part to the non-binding nature 
of the voluntary moratorium, germ-line use of CRISPR has already been used to manipulate fetal 
DNA.23  In 2018, Professor He Jiankui created the first “CRISPR babies” in China,24 a project he 
undertook independent of his academic laboratory.25  Ultimately, there was significant 
international backlash against Professor He’s experiment, and in December 2019, the Chinese 
government sentenced him to three years in prison.26 While the Chinese government may be 
seeking to quell international ethics concerns, criminalization of scientific research will have a 
dangerous chilling effect on scientists performing necessary and beneficial work.27  The United 
States is not immune to germ-line experiments, and it is short-sighted to think that social pressure 
will control the expansion of ethically challenging applications of CRISPR in American 
institutions.28  Researchers in the United States are currently working to apply CRISPR techniques 
to human sperm29 and may rely on funding sources that evade typical regulatory schemes.30  Such 
 
23 See Julia Belluz, Is the CRISPR Baby Controversy the Start of a Terrifying New Chapter in Gene Editing?, VOX 
(January 22, 2019) https://www.vox.com/science-and-health/2018/11/30/18119589/crispr-gene-editing-he-jiankui. 
See also, Pam Belluck, Gene-Edited Babies: What a Chinese Scientist Told an American Mentor, N.Y. Times (April 
14, 2019) https://www.nytimes.com/2019/04/14/health/gene-editing-babies.html. 
24 Id.  
25 See China Says Dr. He Jiankui Behind Gene-Edited Babies Acted on His Own, NBC News: Associated Press (Jan. 
21, 2019, 9:51 AM), https://www.nbcnews.com/health/health-news/china-says-dr-he-jiankui-behind-gene-edited-
babies-acted-n960926. But see Julia Belluz, CRISPR Babies: The Chinese Government May Have Known More Than 
It Let On, Vox (Mar. 4, 2019, 11:00 AM) (suggesting that the project was less “independent” than Chinese officials 
have publicly stated), https://www.vox.com/2019/3/4/18245864/chinese-scientist-crispr. 
26 David Cyranoski, What CRISPR-Baby Prison Sentence Means for Research, NATURE (Jan. 3, 2020), 
https://www.nature.com/articles/d41586-020-00001-y. 
27 Id. 
28 Cf. Francoise Baylis, Before Heritable Genome Editing, We Need Slow Science and Dialogue ‘Within and Across 
Nations’, STAT: First Opinion (September 23, 2019) https://www.statnews.com/2019/09/23/genome-editing-slow-
science-dialogue/. 
29 Rob Stein, Scientists Attempt Controversial Experiment to Edit DNA in Human Sperm Using CRISPR, NPR (August 
22, 2019) https://www.npr.org/sections/health-shots/2019/08/22/746321083/scientists-attempt-controversial-
experiment-to-edit-dna-in-human-sperm-using-cri. 
30 Dr. Gianpiero Palermo, the principal investigator behind CRISPR sperm research in the United States, has created 
the Palermo Foundation, an organization with the mission of “rais[ing] funds to continue research for both male and 
female infertility regardless of the underlying cause.” Palermo Foundation, Our Mission (last visited Feb. 14, 2020), 
https://www.palermofoundation.org/. “The Foundation plans to establish the premises to nest an advanced 
reproductive laboratory . . . As the Foundation gains its reputation, fundraising activities will be organized to gain 
support to build the facility.” Id.  
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germ-line edits would inevitably be passed on to future generations,31 fundamentally altering their 
development.  A middle ground between criminalization and mere social pressure would be helpful 
in controlling the expansion of these efforts before they go too far. 
There is no doubt that the prospect of CRISPR application in a clinical setting has caused 
significant alarm in both scientific and lay communities; however, this alarm has largely been 
narrowed to the germline context, leading to a failure to consider negative consequences of somatic 
application.32  As a result, somatic research regarding CRISPR applications are more likely to 
progress without much questioning.  Professor He’s ability to create CRISPR edited babies reveals 
just how simple and efficient genetic manipulation has become.33  In the United States, clinical 
research on somatic cells currently includes trials for various relapsed cancers, sickle cell anemia, 
non-Hodgkins lymphoma, and inherited blindness.34  More fundamental and pre-clinical research 
is also occurring, and likely to progress quickly.35  The scientific community is rapidly moving 
towards application of CRISPR across a variety of biomedical areas.36  In light of this revolutionary 
shift, somatic applications cannot be ignored. 
The ethical and legal debate cannot stop with germ-line concerns, and it must not be left 
solely to the scientific community.  While germ-line applications are undoubtedly alarming, 
 
31 Is it Ethical to Edit Human Sperm with CRISPR?, ADVISORY BOARD: The Daily Briefing (August 27, 2019) 
https://www.advisory.com/daily-briefing/2019/08/27/crispr. 
32 See, e.g., Joel Achenbach, NIH and Top Scientists Call for a Moratorium on Gene-Edited Babies, Washington Post 
(March 13, 2019, 2:00 PM), https://www.washingtonpost.com/science/2019/03/13/nih-top-scientists-call-
moratorium-gene-edited-babies/; Amy Maxmen, Easy DNA Editing Will Remake the World. Buckle Up., Wired 
(2015), https://www.wired.com/2015/07/crispr-dna-editing-2/. 
33 Id. 
34 Lila Thulin, Four U.S. CRISPR Trials Editing Human DNA to Research New Treatments, Smithsonian Magazine 
(Sep. 3, 2019) https://www.smithsonianmag.com/science-nature/four-us-crispr-trials-editing-human-dna-for-new-
medical-treatments-180973029/. 
35 See generally This is Broad, BROAD INSTITUTE, https://www.broadinstitute.org/about-us. See also Cui Zhang, Renfu 
Quan & Jinfu Wang, Development and Application of CRISPR/Cas9 Technologies in Genomic Editing, 27 HUMAN 
MOL. GENETICS R79 (2018). 




widespread somatic uses are much closer in time and present their own ethical complexities.  Thus, 
this comment will seek to demonstrate the potential implications of somatic editing by examining 
its application in the field of psychiatry and assessing the ability of mental disability law to address 
the negative consequences of such applications.  Section II will outline possible somatic 
applications of CRISPR in psychiatry.  Then, Section III will examine the constitutional 
protections of the bodily autonomy of mentally ill persons and explore the current state of mental 
disability law regarding bodily autonomy.  Finally, Sections IV and V will look to present 
regulatory structures to determine whether they are capable of addressing somatic CRISPR uses 
and consider potential solutions for leaders to adopt moving forward. 
II. Potential for Gene Editing to be Exploited in Psychiatry 
A. In Pursuit of Neurobiological Clarity 
Psychiatry is a particularly pertinent area for CRISPR research for several reasons.  First, 
recent psychiatric research has failed to produce new, effective medications.37  Drug development 
has stalled as new medication targets for psychiatric purposes have not been identified in quite 
some time.38  The most commonly prescribed psychiatric drugs were approved by the FDA more 
than 30 years ago,39 and drugs for diseases such as schizophrenia merely subdue a singular 
symptom of the disease, rather than treating its underlying cause.40  As a result of this relative 
standstill, researchers are seeking out new avenues for potential treatment.41  CRISPR is not only 
being explored as a way to cure or eliminate mental illness, but it is also being looked at, more 
 
37 Why Study the Genetics of Psychiatric Disorders?, BROAD INSTITUTE, 
https://www.broadinstitute.org/files/news/media-kit/WhyStudyGenetics.pdf 
38 Id. 
39 Jim Dryden-Wustl, CRISPR Powers the Hunt for New, Better Antidepressants, FUTURITY (August 17, 2018), 
https://www.futurity.org/antidepressants-crispr-1841722/. 
40 Research Highlight: Schizophrenia, BROAD INSTITUTE (2016), https://www.broadinstitute.org/research-highlights-
schizophrenia. 
41 Dryden-Wustl, supra note 39. 
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immediately, to increase the effectiveness of psychiatric medications.42  Since this research has, at 
a minimum, aided scientific understanding of mental illness, it will likely forge ahead in years to 
come.43 
In addition to the drug development stalemate, psychiatry is a prime area for somatic 
applications of CRISPR due to the highly heritable nature of psychiatric disease.44  Research into 
the etiology of mental illness shows that genetics, in addition to environmental factors, play a 
significant role in the development of mental illness.45  In fact, some of the most debilitating mental 
illnesses are also thought to have the strongest genetic markers,46 and research continues to 
“indicate[] widespread genetic overlap across different types of psychiatric disorders, particularly 
between attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, major depressive 
disorder, and schizophrenia.”47  As a result of these strong genetic links, scientists are beginning 
to explore the possibility of gene editing as a potential treatment avenue for psychiatric illnesses.48  
Ultimately, the impact these diseases have on patients’ lives, combined with the fact that they are 
often difficult to treat, will continue to make them prime targets for CRISPR research and 
 
42 Id. See also Stanley Center Therapeutics Projects, BROAD INSTITUTE: Stanley Center for Psychiatric Research, 
https://www.broadinstitute.org/therapeutics/stanley-center-therapeutics-projects. 
43 See, e.g., Stanley Center Therapeutics Projects, BROAD INSTITUTE: Stanley Center for Psychiatric Research, 
https://www.broadinstitute.org/therapeutics/stanley-center-therapeutics-projects. 
44 Genetic Relationship between Five Psychiatric Disorders Estimated from Genome-Wide SNPs, NATIONAL 
INSTITUTE OF HEALTH: Cross-Disorder Group of the Psychiatric Genomics Consortium, 45, NAT. GEN. 984 (2013). 
45 Stephanie P.B. Caligiuri & Paul J. Kenny, The Promise of Genome Editing for Modeling Psychiatric Disorders, 43 
NEUROPSYCHOPHARMACOLOGY REVIEWS 223 (2018). 
46 These illnesses include major depressive disorder, bipolar disorder, and schizophrenia. Rudolf Uher & Alyson 
Zwicker, Etiology in Psychiatry: Embracing the Reality of Poly-Gene-Environmental Causation of Mental Illness, 16 
WORLD PSYCHIATRY 121 (2017). 
47 Karen Zusi, Psychiatric Disorders Share an Underlying Genetic Basis, BROAD INSTITUTE: News (June 21, 2018), 
https://www.broadinstitute.org/news/psychiatric-disorders-share-underlying-genetic-basis. 
48 Angela She, CRISPR in Neuroscience: How Precision Gene Editing May Unravel How the Brain Works (and Why 
It Sometimes Doesn’t), Harvard University Graduate School of Arts and Sciences: Neurotechnology Blog (April 6, 
2016), http://sitn.hms.harvard.edu/flash/2016/crispr-in-neuroscience-how-precision-gene-editing-may-unravel-how-
the-brain-works-and-why-it-sometimes-doesnt/; Fighting Depression with CRISPR, Synthego: The Bench (August 
23, 2018), https://www.synthego.com/blog/crispr-depression; S.K. Powell, J. Gregory, S. Akbarian & K.J. Brennand, 
Application of CRISPR/Cas9 to the Study of Brain Development and Neuropsychiatric Disease, 82 MOL. CELL 
NEUROSCI. 157 (2017). 
9 
 
application in the clinical setting.  At present, at least two major U.S. institutions have dedicated 
substantial projects to exploring genetically-based treatments of mental illness.49  The Stanley 
Center for Psychiatric Research of the Broad Center of MIT and Harvard, based in Cambridge, 
Massachusetts, is focused on exploring the etiology of schizophrenia and other mental illnesses, 
identifying biomarkers of psychiatric disease, and “above all, [developing] new treatments.”50  
Meanwhile, the University of California at Los Angeles has launched a “Grand Challenge” focused 
on Depression, and the Center for Neurobehavioral Genetics will focus its efforts on developing 
new genetically-based treatments for the illness.51  Ironically referring to the Grand Challenge as 
the “Manhattan Project for depression,” UCLA researchers intend to make a tremendous impact,52 
and there is no doubt that the development of CRISPR technology will help them, and others53, 
move quickly towards their goals.54 
B. Pumping the Brakes on Psychiatric Genetics 
i. Substantive Concerns 
While it clearly makes sense to explore the genetic underpinnings of mental illness, there 
are also a number of reasons why advancement in this area via the application of CRISPR 
 
49 See, e.g., Stanley Center, BROAD INSTITUTE, infra note 50, and UCLA Grand Challenges, infra note 51. 
50 Stanley Center, BROAD INSTITUTE: Stanley Center for Psychiatric Research, https://www.broadinstitute.org/stanley. 
51 See Depression, UCLA GRAND CHALLENGES, https://grandchallenges.ucla.edu/depression/. 
52 Linda Marsa, Can We Eliminate Depression? A Massive New Project Aims to Do Just That, DISCOVER (Oct. 9, 
2019), https://www.discovermagazine.com/mind/can-we-eliminate-depression-a-massive-new-project-aims-to-do-
just-that. 
53 The Virginia Institute for Psychiatruc and Behavioral Genetics at the Virginia Commonwealth University seeks to 
study the genetic etiology of psychiatric illness as well; however, the VCU Institute is pursuing more general 
understandings through foundational research, as opposed to the solution-driven focus of the Broad Institute and 
UCLA’s Grand Challenge. See Virginia Institute for Psychiatric and Behavioral Genetics, Mission Statement (last 
visited Feb. 14, 2020), https://vipbg.vcu.edu/about/mission-statement/. 
54 Interestingly, two of the leaders of the UCLA project identified the first genetic markers of depression by studying 
Chinese women. See id.; Roseann E. Peterson, et al, The Genetic Architecture of Major Depression in Han Chinese 
Women, 74 J. AM. MED. ASS’N PSYCHIATRY 162 (2017). China’s protection of its citizen’s genetic information and 
privacy is questionable at best. See, e.g., Emma Yasinski, China Clamps Down on Foreign Use of Chinese Genetic 
Material and Data, THE SCIENTIST (June 17, 2019), https://www.the-scientist.com/news-opinion/china-clamps-down-
on-foreign-use-of-chinese-genetic-material-and-data-66016; Sui-Lee Wee, China Uses DNA to Track Its People, With 




technology must be approached with extreme caution.  Although mental illness is highly heritable, 
scientists suspect that these illnesses are also polygenic, meaning that multiple genes contribute to 
their pathogenicity.  In addition, the role of epigenetics (changes to the DNA that do not affect the 
sequences themselves but can influence gene expression nonetheless) in the development of 
psychiatric illnesses is not fully understood.55  Both of these aspects of the underlying science can 
apply to diseases that are non-psychiatric in nature, and somatic editing for those illnesses my 
present similar challenges.  These challenges are not only technological, but also presents ethical 
in nature.  For example, primary candidates for initial, experimental uses of psychiatric (and non-
psychiatric) somatic gene-editing will be those patients afflicted with the most serious conditions, 
experiencing the most severe symptoms and facing the greatest amount of treatment resistance via 
conventional treatment methods.56  As these patients are likely desperate for new treatments for 
their illnesses, researchers must have an awareness of the impact such desperation can have on 
patients’ decision-making.57 
In addition to the technological issues presented, polygenicity may pose other concerns as 
well.  The impact that changing only one or two genes contributing to an illness, as opposed to all 
of the genes known to be associated, could have unimaginable and unpredictable consequences.58  
Furthermore, the very nature of what CRISPR technology would seek to do, i.e., “erase” or 
“replace” characteristics at the very core of a person, warrants serious concern and questioning 
about its role in psychiatric treatment and medical care more generally.  This concern about 
 
55 What is epigenetics?, National Institutes of Health: Genetics Home Reference, 
https://ghr.nlm.nih.gov/primer/howgeneswork/epigenome. 
56 Alexandra L. Foulkes, Takahiro Soda, Martilias Farrell, Paola Giusti-Rodriguez & Gabriel Lazaro-Munoz, Legal 
and Ethical Implications of CRISPR Applications in Psychiatry, 97 N.C.L. REV. 1359, 1383-86 (2019), 
https://docs.wixstatic.com/ugd/ba77b5_5d2805bbecea47dbb70ec3eda4fdc199.pdf. 
57 Id. 
58 Carolyn Brokowski & Mazhar Adli, CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool, 
431 J. MOL. BIOL. 88, 90 (2019). 
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“erasing “ characteristics also applies to non-psychiatric diseases, as the manipulation of “bad 
genes” to “good genes” will undoubtedly reduce diversity, neural and otherwise.59, 60 Clinicians 
must engage with patients in a careful risk-benefit analysis that takes into account the individual 
needs of the patient and seeks to ensure that “the risks and burdens that accompany the intervention 
[are not] greater than the baseline state of the individual.”61 They must also carefully consider the 
biological and sociological implications that an inevitable reduction in diversity might have.62 
ii. Procedural Concerns 
Psychiatric research on human patients also involves substantial concerns regarding 
informed consent and voluntary participation.63  Care must be used in the informed consent 
protocol of any experimental application of new technology; however, the nature of mental illness 
is such that eligible patients are at a heightened risk of being taken advantage of and manipulated 
during the medical decision-making process.64  Even the Supreme Court, in Zinermon v. Burch, 
has recognized the inherent concerns regarding the ability of mentally ill patients to provide 
legitimate informed consent regarding their medical treatment: 
The risk is that some persons who come into [the state’s] mental health facilities 
will apparently be willing to sign forms authorizing admission and treatment, but 
will be incompetent to give the “express and informed consent” required for 
voluntary placement under [the statute]. Indeed, the very nature of mental illness 
makes it foreseeable that a person needing mental health care will be unable to 
understand any proffered “explanation and disclosure of the subject matter” of the 
forms that person is asked to sign, and will be unable “to make a knowing and 
willful decision” whether to consent to admission. A person who is willing to sign 
forms but is incapable of making an informed decision is, by the same token, 
 
59 FRANCOISE BAYLIS, ALTERED INHERITANCE: CRISPR AND THE ETHICS OF HUMAN GENOME EDITING 19-35 (2019). 
60 For a discussions of neurodiversity, see John Elder Robison, What is Neurodiversity?, PSYCHOLOGY TODAY (Oct. 
7, 2013), https://www.psychologytoday.com/us/blog/my-life-aspergers/201310/what-is-neurodiversity, and Robert 
D. Austin & Gary P. Pisano, Neurodiversity as a Competitive Advantage, HARVARD BUSINESS REVIEW (June 2017, 
99-103), https://hbr.org/2017/05/neurodiversity-as-a-competitive-advantage. 
61 Laura Weiss Roberts & Shaili Jain, Ethical Issues in Pharmacology, 28 PSYCHIATRIC TIMES (May 7, 2011), 
https://www.psychiatrictimes.com/bipolar-disorder/ethical-issues-psychopharmacology. 
62 BAYLIS, ALTERED INHERITANCE, supra note 59. 
63 John S. Carroll, Consent to Mental Health Treatment: A Theoretical Analysis of Coercion, Freedom, and Control, 




unlikely to benefit from the voluntary patient’s statutory right to request discharge. 
. . . Such a person thus is in danger of being confined indefinitely without benefit 
of the procedural safeguards of the involuntary placement process, a process 
specifically designed to protect persons incapable of looking after their own 
interests.”65 
Thus, the increased vulnerability of the mentally ill can make it difficult to determine whether 
consent without coercion has truly been given.66  These concerns are likely present with other 
vulnerable populations as well, such as minors or developmentally delayed individuals.  
Furthermore, the stigma surrounding mental illness is of particular concern for psychiatric patients, 
as this stigma has the potential to lead to force, manipulation, or inappropriate persuasion from 
medical professionals and family members, whether these individuals are aware of their impact or 
not.67  Shame and emotional pain associated with psychiatric disease may encourage an 
individual’s loved ones to assert significant pressure to accept treatment, leading to consent that is 
not truly voluntary and autonomous.68 
 In addition to the concerns surrounding informed consent, use of CRISPR in the psychiatric 
context also warrants serious consideration regarding patient privacy.  Whether CRISPR is used 
to directly modify a patient’s DNA or derivatives of the technology are used to identify better 
pharmacological treatment options, application of CRISPR in the clinical psychiatric context will 
“likely require collecting participant’s genetic information.”69  Genetic privacy is not the only 
concern here—privacy of mental health records is also of extreme importance, especially due to 
the widespread stigma about psychiatric diagnoses that persists in society.70  Since genetic 
information will be directly tied to data about a patient’s mental health status, “clinicians and 
 
65 Zinermon v. Burch, 494 U.S. 113, 133 (1990). 
66 John S. Carroll, supra note 63. 
67 Id. at 130. 
68 Id. at 131. 




researchers should take particular care to protect this population from improper disclosure and 
misuse of medical information.”71 
III. Constitutional Authority on the Bodily Autonomy of the Mentally Ill 
Most Americans would recognize that bodily autonomy is a fundamental right possessed 
by all persons and that this right is treated with such high regard in our legal system that little can 
overcome it.  These ideas are supported by the longstanding “recogni[tion] of the common law 
right against bodily intrusions,”72 evidenced “in the torts of battery and trespass.”73  Despite the 
fact that bodily autonomy “is considered among the most cherished of rights,”74 the Supreme 
Court’s treatment of the bodily autonomy of vulnerable groups, such as the mentally ill, 
complicates this view75—“[f]ailure to appreciate the true invasiveness of many bodily intrusions 
has made the Court exceedingly deferential to state authority and ‘professional judgment’ in 
deciding when intrusions are necessary.”76  Ultimately, the jurisprudence of our nation’s highest 
Court reveals that respect for individual bodily autonomy is substantially undermined by the 
Court’s treatment of persons traditionally seen as “biologically inferior”.  This Section will 
examine jurisprudence regarding the mentally ill; however, the notion of “biological inferiority” 
extends beyond this context and has been evidenced in both our nation’s and the world’s history.77 
 
71 Id. 
72 Caitlin E. Borgmann, The Constitutionality of Government-Imposed Bodily Intrusions, 2014 U. ILL. L. REV. 1059, 
1060 (2014). 
73 Id. at 1064. 
74 Id. at 1060. 
75 See infra Sections III(A)–(C). 
76 Borgmann, supra note 72, at 1062. 
77 Such beliefs became popular during the 1800s after Charles Darwin published his “survival of the fittest” theory, 
which sparked the rise of Social Darwinism. Social Darwinism, HISTORY (Aug. 21, 2018), 
https://www.history.com/topics/early-20th-century-us/social-darwinism. These ideas have been applied to various 
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“biological inferiority”, persists in the modern era. See W. Carson Byrd & Matthew W. Huey, Born That Way? 
‘Scientific’ Racism is Creeping Back into Our Thinking. Here’s What to Watch Out For., WASH. POST (Sept. 28, 
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A. Forced Sterilization 
The starkest example of disrespect for the bodily autonomy of “biologically inferior” 
mentally ill persons can be seen in the Court’s infamous opinion in Buck v. Bell.  In Buck, the 
Court upheld the constitutionality of forced sterilization for “feeble-minded imbeciles” that were 
being held in state-run institutions.78  Carrie Buck, a supposedly mentally ill woman,79 had been 
committed to the state mental institution “in due form,”80 language intended to suggest that her 
due process rights had not been violated.   Buck’s mother was also mentally ill, and Buck, herself, 
was the mother of a mentally ill child.81  As a result of her “feeble-minded” lineage, Ms. Buck was 
subjected to a surgical sterilization procedure at the discretion of the institution’s superintendent.82  
She was just eighteen years old at the time.83  In upholding the constitutionality of the procedure 
against a Fourteenth Amendment challenge, Justice Holmes stated: “[i]t is better for all the world, 
if . . . society can prevent those who are manifestly unfit from continuing their kind.”84 
Though Buck v. Bell is an old case, it has never been directly overturned by the Court85, 
and the Court has explicitly declined the opportunity to do so.86  The case has been dismissed as a 




78 Buck v. Bell, 274 U.S. 200 (1927). 
79 See, e.g., Paul A. Lombardo, Three Generations, No Imbeciles: New Light on Buck v. Bell, 60 N.Y.U.L. REV. 30, 
52 (1985) (evidence not presented at trial could have refuted the assertion that Carrie Buck was, in fact, mentally 
deficient). 
80 Buck, 274 U.S. at 205. 
81 Id. For a debate regarding whether Carrie Buck’s mother and daughter actually did suffer from mental illness, see 
generally Lombardo, supra note 79. 
82 Buck, 274 U.S. at 205–06. 
83 Id. at 205. 
84 Id. at 207. 
85 See, e.g., David Bianculli, The Supreme Court Ruling that Lead to 70,000 Forced Sterilizations, NATIONAL PUBLIC 
RADIO: FRESH AIR (March 24, 2017, 3:46 PM), https://www.npr.org/2017/03/24/521360544/the-supreme-court-
ruling-that-led-to-70-000-forced-sterilizations. 
86 See Skinner v. Oklahoma, 316 U.S. 535 (1942) (holding that the Oklahoma Habitual Criminal Sterilization Act 
unconstitutional because the law was applied differently to habitual criminals based on the types of crimes they 
committed but refusing to apply this reasoning to mentally ill persons). 
87 See, e.g., Chamul v. Amerisure Mut. Ins. Co., 486 S.W.3d 116, 117 (TX Ct. App., 1st District, 2016). 
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validity of this idea is, at best, questionable, since forced sterilization was a contentious issue even 
in 1927 when the case was decided.88  Despite the repudiation that has occurred, its continuance 
as a case that has merely been questioned, rather than overturned, leaves the door open for highly 
invasive, government-imposed procedures to be held constitutional.  Ultimately, “Buck [continues 
to] represent[] a milestone in the affirmation of governmental power over individual rights, but 
more specifically, Buck is a landmark in the endorsement of intrusive medical procedures as tools 
to be used for state ends.”89  Its continued presence in the Supreme Court’s jurisprudence poses a 
dangerous precedential threat in our present genetic age. 
B. Forced Medication 
While Mills v. Rogers is less obviously problematic than Buck v. Bell, the case still serves 
to undermine the rights of mentally ill persons within the American justice system.  Mills v. Rogers 
involved coerced administration of medication to a mentally ill patient, and the parties involved 
decided to stipulate at trial that a liberty interest in avoiding such administration of psychoactive 
drugs exists.90  This stipulation ultimately enabled the Supreme Court to avoid determining 
whether such an interest is protected by the Constitution.91  In assuming the stipulation, the Court 
leaves room for an argument against a Constitutional right against this sort of bodily intrusion, 
weakening the protection the Constitution provides to psychiatric patients.  Furthermore, the Court 
uses a circular argument to avoid saying anything substantive on the matter.  Relying on the 
stipulated assumption that a liberty interest in avoiding forced medication exists, the Court asserts 
 
88 Alex Wellersterin, States of Eugenics: Institutions and Practices of Compulsory Sterilization in California, 
REFRAMING RIGHTS: BIOCONSTITUTIONALISM IN THE GENETIC AGE (Sheila Jasanoff ed., 2011) at 32. 
89 Lombardo, supra note 79, at 33.  
90 Mills v. Rogers, 457 U.S. 291, 299 (1982). 
91 Id. at 299 n.16. 
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that state law could only increase any interest that may exist, yet still fails to provide any guidance 
regarding how these interests are to be assessed or balanced against state interests.92  
By essentially punting on whether individuals actually do have a liberty interest in avoiding 
forced medication, the Supreme Court left the question open for lower courts to decide in a 
scattered and hesitant manner.93  In asserting that federal constitutional requirements for due 
process do not control and leaving such process concerns to states to decide, the Court underlined 
its refusal to apply strict scrutiny in cases concerning government intrusions of bodily autonomy,94 
and left open a black hole in which the Eleventh Amendment could be asserted by states against 
the rights of the individual.95  After a slew of litigation between state and federal courts, the Rogers 
litigation ultimately ended with the First Circuit deciding that state level protections were 
sufficient.96 
C. Involuntary Commitment 
The Supreme Court’s lack of respect for the bodily autonomy of the mentally ill can even 
be seen in its jurisprudence around involuntary civil commitment.  In Addington v. Texas, the 
constitutionality of indefinite civil commitment to a mental hospital was challenged.97  Frank 
Addington was sentenced to involuntary commitment for an indefinite period of time following a 
conviction of “assault by threat” on the basis of a “clear and convincing evidence” standard.98  
Addington appealed, arguing that the jury should have been instructed on the basis of a “beyond a 
reasonable doubt” standard.99  Ultimately, despite the fact that such involuntary commitment 
 
92 Id. at 299–300. 
93 Ellen Wright Clayton, From Rogers to Rivers: The Rights of the Mentally Ill to Refuse Medication, 13 AM. J.L. & 
MED. 7, 39–40 (1987). 
94 Caitlin E. Borgmann, supra note 72, at 1059. 
95 Ellen Wright Clayton, supra note 93, at 41–43. 
96 Id. at 43. 
97 Addington v. Texas, 441 U.S. 418 (1979). 
98 Id. at 421. 
99 Id. at 421–22. 
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would have the same impact on Addington’s bodily autonomy as a prison sentence, the Supreme 
Court upheld the use of the lesser evidentiary standard, stating that it did not violate due process 
when used for civil confinement purposes.100  
The Addington opinion also suggests that substantial deference should be given to 
psychiatric professionals for purposes of the balancing test required in the civil commitment 
context.101  Since the courts must balance both the interests of the individual (in not being confined) 
and the interests of the state (under its parens patriae powers),102 the “beyond a reasonable doubt” 
standard is too high a burden for a juror to assess on the basis of a psychiatrist’s evaluation of 
“whether the individual is mentally ill and . . . is in need of confined therapy.”103  Thus, the Court 
is essentially applying “therapeutic jurisprudence” to “permit[] the state, in the name of therapy, 
to deprive people of their liberty without the ‘great safeguards’ of the criminal law,” and relegating 
mentally ill persons to a lesser personhood status in the legal system.104 
D. Current Status of Mental Disability Law 
i. The Impact and Legacy of Sell 
Coinciding with the rise in gene editing technology, has been relative silence on the part 
of the Supreme Court to rule on issues that protect the bodily autonomy of the mentally ill.  The 
Court’s most recent case, Sell v. United States, was decided over 15 years ago, when CRISPR was 
still in the earliest stages of its development as a gene editing tool.105  In Sell, the Court determined 
that the constitutionality of involuntary administration of antipsychotics to render an individual 
 
100 Id. at 428–29. 
101 Id. at 429–30. 
102 Id. at 425–26. 
103 Addington, 411 U.S. at 418, 429–30. 
104 Eric S. Janus, Preventing Sexual Violence: Setting Principled Constitutional Boundaries on Sex Offender 
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competent to stand trial is based on a balancing test.106  This test considers (1) whether the 
treatment is medically appropriate, (2) whether the treatment is substantially unlikely to have side-
effects that may undermine the trial’s fairness, and (3) whether, in the absence of less intrusive 
alternatives, the treatment is necessary significantly to further important governmental, trial-
related interests.107  Though the Court attempted to narrow its holding only to the criminal 
“competency to stand trial” context, the Sell test ultimately implies that a “dangerousness” 
determination is not required to coerce an uncooperative mental patient to undergo treatment with 
antipsychotic medication.108  Thus, the coercion determination is largely rooted in the assessment 
and treatment decisions of medical personnel, rather than allowing the individual to maintain her 
dignity in determining the medical treatment she wishes to receive. 
Though Sell is a case based on criminal law, the standard it sets has broader implications 
outside the criminal context.109  The distinction between civil and criminal law in the development 
of mental health disability law has been significantly blurred, with varying standards being set in 
each context.110  “Patent decisional inconsistency” can be seen in the way the Supreme Court’s 
jurisprudence has developed with regard to the Constitutional rights of the mentally ill, and 
“different substantive and procedural standards have been imposed in [a number of] cases” 
involving the right to refuse medication.111  Furthermore, “the Court is equally comfortable with 
pretextually characterizing what are clearly criminal penalties . . . as civil so as to save them from 
constitutional challenge.”112  Thus, the implications of Sell may extend beyond the trial 
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competency setting, rendering a patient’s ability to refuse medication virtually obsolete where a 
medical necessity determination has been made. 
IV. Regulatory Control Over CRISPR Technology 
Given that constitutional bodily autonomy protections are likely insufficient to protect from 
inappropriate somatic uses of CRISPR in the psychiatric context, state and federal laws and 
regulations will be relied on to prevent inappropriate use.  While state law has the potential to 
provide greater protection and can serve as a “gap filler” in the niche areas that issues such as 
CRISPR create, state laws also lack uniformity and have a minimal influence on the scientific 
community and biomedical industry as a whole.113  Thus, federal regulation must carry the brunt 
of the responsibility in shaping and maintaining the legal landscape regarding gene therapy and 
CRISPR technology.  
A. Coordinated Framework 
At present, federal regulation fails to sufficiently protect mentally ill patients from 
improper applications of gene editing technologies such as CRISPR.114  The Coordinated 
Framework for the Regulation of Biotechnology was first issued in 1986 by the White House 
Office of Science and Technology Policy to clarify the roles of major administrative agencies in 
regulating biotechnology products.115  While the Coordinated Framework provides “fundamental 
federal guidance for regulating biotechnology products” and is intended to ensure oversight using 
already established federal agencies,116 it is unclear whether these goals are being sufficiently 
 
113 Cf. M. ARIEL CASCIO & ERIC RACINE, RESEARCH INVOLVING PARTICIPANTS WITH COGNITIVE DISABILITY AND 
DIFFERENCES: AUTONOMY, INCLUSION, AND INNOVATION, OXFORD UNIVERSITY PRESS (2019), at 255. 
114 Cf. Advanced Gene Editing: CRISPR-Cas9, Congressional Research Service Report No. R44824 (last updated Dec. 
7, 2018), at 11. 
115 Modernizing the Regulatory System for Biotechnology Products: Final Version of the 2017 Update to the 
Coordinated Framework for the Regulation of Biotechnology, Executive Office of the President: Biotechnology 
Working Group (2017), at 2–3, 
https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/2017_coordinated_framework_update.pdf. 
116 Advanced Gene Editing: CRISPR-Cas9, supra note 114, at 9. 
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achieved.117  “Despite recent efforts to update the Coordinated Framework, CRISPR-Cas9 
technology and other gene-editing systems raise substantive questions about how (or whether) the 
products resulting from these technologies are to be regulated, and if so, under what statutory 
authorities.”118  This confusion has persisted since the 2017 update to the Coordinated Framework, 
which explicitly left questions regarding genome editing and CRISPR technology to be decided 
by future regulatory activities.119 
As CRISPR is an emerging technology, the vast majority of its present use is in an 
experimental context, leaving it outside of the FDA’s product safety regulatory authority.  The 
FDA “can impose requirements on research as a condition for receiving either federal funding or 
FDA premarket review of a new medical product (such as a drug, device, or biologic);”120 however, 
given that CRISPR is in a nascent stage, the FDA has yet to be faced with these challenges in any 
substantially meaningful way.  If the “federal tie” of government funding or premarket review is 
absent, the FDA lacks jurisdiction over CRISPR research. As suggested earlier, this lack of 
jurisdiction is not merely hypothetical, as researchers have shown willingness to seek private 
sources of funding located outside the reach of federal regulation. 
The FDA’s role in regulating CRISPR may remain complicated even within the product 
safety context, as FDA regulation of a given product depends on whether it falls into one of the 
specific categories over which the FDA has jurisdiction.121  The FDA has issued a short statement 
regarding the self-administration of gene therapy, stating that “FDA considers any use of 
CRISPR/Cas9 gene editing in humans to be gene therapy” regulated under the category of 
 
117 Advanced Gene Editing: CRISPR-Cas9, supra note 114, at 11. 
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biologics.122 While courts generally defer to category determinations made by the FDA, deference 
by the federal courts does not always occur.123  Furthermore, the FDA’s statement notes that “the 
sale of these products is against the law.”124 Thus, in the absence of explicit statutory authority, 
the door to legal arguments against FDA jurisdiction remains open to challenges based on both 
statutory definitions and Commerce Clause limitations.125  
Despite these challenges, the FDA has shown willingness to regulate gene therapies that it 
does determine are within its jurisdiction, and it has recognized a need to keep FDA regulations 
current with technological advances.126  For example, FDA guidance released in 1998 expanded 
the regulatory requirements for clinical trials involving gene therapies so that greater emphasis 
was placed on the disclosure of potential adverse events.127  In a moment where researchers appear 
to be looking for regulatory guidance,128 the FDA should follow its own precedent.  As it has done 
with similarly controversial technologies, namely recombinant DNA technology, gene therapy and 
cloning,129 the FDA must find a way to categorize the CRISPR so that it falls under FDA 
jurisdiction.  While such an assertion may not be failproof, it will provide the guidance the industry 
is seeking and prevent the technology from falling into a regulatory tailspin. 
B. 21st Century Cures Act  
In December 2016, the federal regulatory restrictions on emerging technologies, including 
CRISPR, were relaxed as a result of the enactment of the 21 Century Cures Act (hereinafter, Cures 
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Act).  “[D]esigned to help accelerate medical product development and bring new innovations and 
advances to patients who need them faster and more efficiently,” the Cures Act seeks to reduce 
bureaucratic impediments to clinical applications of precision medicine technologies.130  The 
Cures Act includes a number of measures that, although oriented towards efficiency, will likely 
have unintended safety consequences. 
Sections 2011 through 2014 of the Cures Act are aimed at “Advancing Provision 
Medicine” and amends the Public Health Service Act, which allows for FDA regulation of 
biologics.131  The Cures Act provisions are largely focused on data analysis and patient privacy in 
the context of biomedical research.132  While the Cures Act arguably creates greater protections 
for patients’ information by requiring that a certificate of confidentiality is issued to research 
participants,133 the Act’s overall emphasis on data sharing and interoperability generates concerns 
regarding data management and abuse.134  Given that CRISPR applications would likely require 
sequencing of a patient’s genome, research participating in Cures Act-related data sharing places 
patients at risk of serious harm should genetic data be used inappropriately.135 
In addition to Sections 2011 through 2014, Section 3023 of the Cures Act addresses the 
protection of human research subjects. Section 3023 requires the Secretary of Health and Human 
Services to harmonize human research regulations across federal agencies “[i]n order to simplify 
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and facilitate compliance by researchers with applicable regulations.”136  The Cures Act further 
requires that the harmonization “reduce regulatory duplication and unnecessary delays.”137  This 
requirement resulted in the 2019 update to the Common Rule, discussed below. 
C. Common Rule 
The largely experimental nature of present CRISPR uses allows the Common Rule to play 
a substantial role in regulating the technology’s use.  The Common Rule (the Federal Policy for 
the Protection of Human Subjects) was created in response to the Belmont Report, published in 
1979,138 which outlined the main ethical principles to be safeguarded in conducting biomedical 
and behavioral research with human participants.139  These main principles include (1) respect for 
persons, (2) beneficence, and (3) justice, and they correlate to three practical measures that 
researchers can take: informed consent, assessment of risk and potential benefits, and selection of 
participants.140  The Belmont Report led to a revision of FDA regulations that “placed primary 
emphasis on obtaining and documenting voluntary and informed consent, but provided little 
guidance on assessment of risk and potential benefit or the selection of research participants.”141  
In addition to the Belmont Report and the associated FDA revisions, the President’s Commission 
for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research called for 
standardization of research regulations across government agencies.142  Following this call, the 
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Common Rule was created to codify the goals set forth by the Belmont Report and ensure their 
application throughout the biomedical and behavioral research fields.143 
 The initial version of the Common Rule was created in 1981 and set out compliance 
guidelines in accordance with the ethical principles of the Belmont Report;144 however, the Rule 
suffers from limitations of its own.  It is limited in its reach—the Common Rule applies only to 
those studies that “(1) meet certain jurisdictional requirements[], (2) involve ‘research,’ and (3) 
involve the use of ‘human subjects.’”145  As with FDA restrictions, the Common Rule 
jurisdictional requirement involves a federal tie (e.g., federal funding) for the Rule to apply:146 
“[i]f federal funds are not involved or if regulatory approval is not required, research activities 
involving humans might not be subject to any form of oversight.”147  While it may be difficult to 
imagine a large-scale study where a federal tie is not present, regulators should not discount private 
actors.  Since CRISPR technology is relatively affordable, it will be accessible to individuals 
without the jurisdictional “hook”.148  For instance, an activist “biohacker” has already begun DIY 
CRISPR experimentation on his own body while selling “kits” to online purchasers.149  
 The most recent update to the Common Rule was published in 2019150 and focuses on 
requirements for informed consent.  Since the Rule is intended to ensure “(1) respect for the 
autonomous decision-making of those capable of providing it and (2) []protection for persons with 
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diminished autonomy . . . the Common Rule seeks to ensure voluntary participation through 
informed consent.”151  The 2019 revisions sought to redesign consent standards in an attempt to 
streamline the informed consent process.152  As a result, the updated Common Rule requires that 
informed consent procedures involve the application of a “‘reasonable person’ standard for 
research disclosure, require[s] informed consent forms to begin with a ‘concise and focused 
presentation’ of ‘key information,’ and authorize[s] individuals to provide ‘broad consent’ to 
future research with identifiable data and biospecimens.”153  Whether these provisions will reduce 
“administrative burden” while maintaining protections for human research subjects is debatable, 
and the changes may open participants up to even greater vulnerability.154 
 In addition to the changes to informed consent protocols, the Revised Common Rule 
contains definitional adjustments, including in its references to persons with mental impairments.  
The term “mentally disabled persons” has been removed and replaced with “individuals with 
impaired decision-making capacity.”155  Arguably, this change means that those diagnosed with 
psychiatric disorders are no longer explicitly included as a “vulnerable population” under the 
Rule.156  It is unclear what impact this will have on participants with mental illness involved in 
psychiatric research.157  Notably, the Revised Common Rule fails to address Belmont Report goals 
other than informed consent.  Further guidance on selection of participants would have been 
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particularly pertinent in the psychiatric research context, as these patients are particularly 
vulnerable to coercion in the consent process.158 
D. Other Sources of Guidance and Potential Solutions 
While a thorough examination of the international debate on CRISPR research is outside 
the scope of this article, the ideas arising out of that debate may provide important insights to 
consider in the development of domestic CRISPR policy.  Several international organizations have 
begun working on CRISPR policy.  For example, the World Health Organization has established 
an advisory committee to examine genome editing issues, but the committee’s work is still 
developing.159  In addition to the WHO Committee, the International Commission on Clinical Use 
of Heritable Human Genome Editing is also developing guidance,160 and the UK Fertilization and 
Embryology Authority, though dedicated to assisted reproductive technology, may be an important 
resource regarding how to approach bioethics questions regarding genetics.161  Notably, however, 
as in the United States, the primary concern of the international discussion has been germ-line 
editing.162  Thus, the international community has largely ignored the use of genetic editing in 




159 Cf. WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human 
Genome Editing, WORLD HEALTH ORGANIZATION, https://www.who.int/ethics/topics/human-genome-
editing/committee-members/en/; Emmanuelle Tuerlings, Background Paper Governance 1 Human Genome Editing, 
WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome 
Editing (Mar. 2019), https://www.who.int/ethics/topics/human-genome-editing/WHO-Commissioned-Governance-1-
paper-March-19.pdf. 
160 International Commission on Clinical Use of Heritable Human Genome Editing, National Academies of Sciences, 
Engineering & Medicine, http://nationalacademies.org/gene-editing/international-commission/index.htm. 
161 How We Regulate, Human Fertilisation & Embryology Authority, https://www.hfea.gov.uk/about-us/how-we-
regulate/. 




There is presently no binding international consensus on the use of CRISPR technology;164, 
165 however, the creation of laws and policies at the national level can act as an important influence 
in guiding corporate research and development decisions: 
There are government guidelines in other areas as well. These provisions 
technically are not enforceable, and yet they are very strongly persuasive because 
complying with them creates what essentially is a safe haven for companies. They 
know that if they stay within the guidelines, they are not going to run afoul of some 
actual regulation or law. These guidelines also create strong social norms . . . from 
which nations feel free to deviate only when they can provide justification that it is 
necessary to achieve some public benefit.166  
Government-created, binding guidelines are therefore essential.167  While ethical discussions 
within the scientific community are important to foster debate and establish some social consensus, 
these discussions, as evidenced by Professor He’s “CRISPR babies”, do little to ensure actual 
adherence.168  Clear and straightforward regulation from domestic governments might create 
sufficient industry pressure to keep rogue experiments like He’s from reoccurring. 
 In the United States, the requisite clarity would ideally come from Congress in the form of 
a statute outlining strict limitations on both somatic and germline applications of CRISPR 
technology; however, present legislative paralysis suggests that a federal statute is unlikely at any 
point in the near future.169  In the meantime, the FDA should seek to provide greater informal 
guidance to industry, outlining how CRISPR fits into the current regulatory scheme and 
prohibiting its use on individuals under sixteen and other vulnerable populations.  In addition, the 
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FDA should require that clinical trials involving CRISPR employ a “Common Rule plus” approach 
to informed consent, where researchers must show that they have outlined the potential risks 
associated with CRISPR treatment and provided the patient with adequate time to consider his or 
her options.  Furthermore, as CRISPR is first and foremost a methodology, states should seek to 
pass legislation or professional board guidance limiting somatic use of CRISPR to patients over 
the age of sixteen, where strict informed consent procedures are followed, the treatment is 
medically necessary, and alternative treatment options prove substantially deficient in managing 
the patient’s illness.  Such state laws will allow for regulation of the practice of medical 
applications of CRISPR, not just the sale of a product (which may not even be necessary to perform 
CRISPR edits), and prevent a legal vacuum should federal law prove insufficient. 
V. Conclusion 
Many of the more concerning applications of CRISPR technology are still far off in reality; 
however, leaders should take this opportunity to get ahead of the science in a realm where policy 
is often far outpaced by technology.  As the psychiatric context makes clear, somatic applications 
may be just as problematic as germ-line uses of CRISPR, and we must carefully consider the 
consequences of engaging in biological manipulations that cut to the core of an individual’s 
personhood.  It is doubtful Constitutional protections will be sufficient once gene editing becomes 
widespread, especially as applied to mentally ill persons who are civilly committed or otherwise 
institutionalized.  As used in the experimental context, clear regulatory guidance from the FDA, 
NIH, and similar agencies would not only serve American researchers, but could help to shape 
industry standards and encourage the development of international policies that carry more weight.  
CRISPR must be taken seriously, even in its somatic applications, and the government should seek 
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to develop ironclad protections that enable those patients desperate for novel treatments to receive 
care without being unnecessarily placed at risk. 
